|
1
|
Mahdavifar N, Ghoncheh M, Pakzad R,
Momenimovahed Z and Salehiniya H: Epidemiology, incidence and
mortality of bladder cancer and their relationship with the
development index in the world. Asian Pac J Cancer Prev.
17:381–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leblanc B, Duclos AJ, Bénard F, Côté J,
Valiquette L, Paquin JM, Mauffette F, Faucher R and Perreault JP:
Long-term followup of initial Ta grade 1 transitional cell
carcinoma of the bladder. J Urol. 162:1946–1950. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palou J, Sylvester RJ, Faba OR, Parada R,
Peña JA, Algaba F and Villavicencio H: Female gender and carcinoma
in situ in the prostatic urethra are prognostic factors for
recurrence, progression, and disease-specific mortality in T1G3
bladder cancer patients treated with bacillus Calmette-Guerin. Eur
Urol. 62:118–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Uro. 71:447–461. 2017. View Article : Google Scholar
|
|
6
|
Suehiro Y, Furuya T, Sasaki K and Hinota
Y: DNA polymorphisms. Rinsho Byori. 61:1001–1007. 2013.(In
Japanese). PubMed/NCBI
|
|
7
|
Shlien A and Malkin D: Copy number
variations and cancer. Genome Med. 1:622009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wain LV, Armour JA and Tobin MD: Genomic
copy number variation, human health, and disease. Lancet.
374:340–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang F, Gu W, Hurles ME and Lupski JR:
Copy number variation in human health, disease, and evolution. Annu
Rev Genomics Hum Genet. 10:451–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fanciulli M, Petretto E and Aitman TJ:
Gene copy number variation and common human disease. Clin Genet.
77:201–213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diskin SJ, Hou C, Glessner JT, Attiyeh EF,
Laudenslager M, Bosse K, Cole K, Mossé YP, Wood A, Lynch JE, et al:
Copy number variation at 1q21.1 associated with neuroblastoma.
Nature. 459:987–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim
ST, Sun J, Wiklund F, Wiley K, Isaacs SD, et al: Association of a
germ-line copy number variation at 2p24.3 and risk for aggressive
prostate cancer. Cancer Res. 69:2176–2179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lucito R, Suresh S, Walter K, Pandey A,
Lakshmi B, Krasnitz A, Sebat J, Wigler M, Klein AP, Brune K, et al:
Copy-number variants in patients with a strong family history of
pancreatic cancer. Cancer Biol Ther. 6:1592–1599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thean LF, Loi C, Ho KS, Koh PK, Eu KW and
Cheah PY: Genome-wide scan identifies a copy number variable region
at 3q26 that regulates PPM1L in APC mutation-negative familial
colorectal cancer patients. Genes Chromosomes Cancer. 49:99–106.
2010.PubMed/NCBI
|
|
15
|
Yoshihara K, Tajima A, Adachi S, Quan J,
Sekine M, Kase H, Yahata T, Inoue I and Tanaka K: Germline copy
number variations in BRCA1-associated ovarian cancer patients.
Genes Chromosomes Cancer. 50:167–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suehiro Y, Okada T, Shikamoto N, Zhan Y,
Sakai K, Okayama N, Nishioka M, Furuya T, Oga A, Kawauchi S, et al:
Germline copy number variations associated with breast cancer
susceptibility in a Japanese population. Tumour Biol. 34:947–952.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sobin LH, Gospodarowicz M and Wittekind C:
TNM classification of malignant tumors. 7th. UICC International
Union Against Cancer; pp. 262–265. 2009
|
|
18
|
Mostofi FK, Sobin LH and Torloni H:
Histologic typing of urinary bladder tumorsInternational
Histological Classification of Tumors. No. 10. World Health
Organization; Geneva: 1973
|
|
19
|
Chen S, Cao P, Dong N, Peng J, Zhang C,
Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, et al: PCSK6-mediated
corin activation is essential for normal blood pressure. Nat Med.
21:1048–1053. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Molloy SS, Anderson ED, Jean F and Thomas
G: Bi-cycling the furin pathway: From TGN localization to pathogen
activation and embryogenesis. Trends Cell Biol. 9:28–35. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lapierre M, Siegfried G, Scamuffa N,
Bontemps Y, Calvo F, Seidah NG and Khatib AM: Opposing function of
the proprotein convertases furin and PACE4 on breast cancer cells'
malignant phenotypes: Role of tissue inhibitors of
metalloproteinase-1. Cancer Res. 67:9030–9034. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Wang L and Pan J: PACE4 regulates
proliferation, migration and invasion in human breast cancer
MDA-MB-231 cells. Mol Med Rep. 11:698–704. 2015.PubMed/NCBI
|
|
23
|
Kang S, Zhao Y, Hu K, Xu C, Wang L, Liu J,
Yao A, Zhang H and Cao F: miR-124 exhibits antiproliferative and
antiaggressive effects on prostate cancer cells through PACE4
pathway. Prostate. 74:1095–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahloogi H, Bassi DE and Klein-Szanto AJ:
Malignant conversion of non-tumorigenic murine skin keratinocytes
overexpressing PACE4. Carcinogenesis. 23:565–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu Y, Campbell EJ, Shepherd TG and
Nachtigal MW: Epigenetic regulation of proprotein convertase PACE4
gene expression in human ovarian cancer cells. Mol Cancer Res.
1:569–576. 2003.PubMed/NCBI
|
